Transarterial radioembolisation (TARE) - basics and clinical use:
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Bremen
UNI-MED Verlag AG
2021
|
| Ausgabe: | 1st edition |
| Schriftenreihe: | UNI-MED science
|
| Schlagworte: | |
| Online-Zugang: | Inhaltstext Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | 112 Seiten Illustrationen 25 cm, 359 g |
| ISBN: | 9783837416039 3837416038 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV048418449 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 220823s2021 gw a||| |||| 00||| eng d | ||
| 015 | |a 21,N51 |2 dnb | ||
| 015 | |a 22,A21 |2 dnb | ||
| 016 | 7 | |a 1247562921 |2 DE-101 | |
| 020 | |a 9783837416039 |c Festeinband : EUR 4.95 (DE), EUR 5.10 (AT), CHF 9.40 (freier Preis) |9 978-3-8374-1603-9 | ||
| 020 | |a 3837416038 |9 3-8374-1603-8 | ||
| 024 | 3 | |a 9783837416039 | |
| 035 | |a (OCoLC)1289783490 | ||
| 035 | |a (DE-599)DNB1247562921 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-HB | ||
| 049 | |a DE-19 | ||
| 082 | 0 | 4 | |a 615.842 |2 23/ger |
| 084 | |8 1\p |a 610 |2 23sdnb | ||
| 100 | 1 | |a Hoffmann, Ralf-Thorsten |d 1971- |e Verfasser |0 (DE-588)122135326 |4 aut | |
| 245 | 1 | 0 | |a Transarterial radioembolisation (TARE) - basics and clinical use |c Ralf-Thorsten Hoffmann, Klaus Zöphel ; in collaboration with Mark Arntz [und weiteren] |
| 250 | |a 1st edition | ||
| 264 | 1 | |a Bremen |b UNI-MED Verlag AG |c 2021 | |
| 300 | |a 112 Seiten |b Illustrationen |c 25 cm, 359 g | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED science | |
| 650 | 0 | 7 | |a SIRT |0 (DE-588)7626011-2 |2 gnd |9 rswk-swf |
| 653 | |a Transarterial radioembolisation | ||
| 653 | |a TARE | ||
| 653 | |a SIRT | ||
| 653 | |a Transarterial radioembolisation;TARE;SIRT | ||
| 689 | 0 | 0 | |a SIRT |0 (DE-588)7626011-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Zöphel, Klaus |d 1967- |e Verfasser |0 (DE-588)121035808 |4 aut | |
| 710 | 2 | |a UNI-MED Verlag AG |0 (DE-588)1065561733 |4 pbl | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |a Hoffmann, Ralf-Thorsten, 1971- |t Transarterial radioembolisation (TARE) – basics and clinical use |b 1. Auflage |d Bremen : UNI-MED Verlag AG, 2021 |h Online-Ressource, 111 Seiten, 80 Illustrationen |
| 856 | 4 | 2 | |m X:MVB |q text/html |u http://deposit.dnb.de/cgi-bin/dokserv?id=dc24957538c2477b9a4e1e7ccc6a7b1e&prov=M&dok_var=1&dok_ext=htm |3 Inhaltstext |
| 856 | 4 | 2 | |m B:DE-101 |q application/pdf |u https://d-nb.info/1247562921/04 |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033796786&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-033796786 | ||
| 883 | 2 | |8 1\p |a dnb |d 20220518 |q DE-101 |u https://d-nb.info/provenance/plan#dnb | |
Datensatz im Suchindex
| _version_ | 1804184332894470144 |
|---|---|
| adam_text | CONTENTS
11
CONTENTS
M
INTRODUCTION
16
1.1.
REFERENCES......................................................................................................................................
17
M
LEGAL
AND
INFRASTRUCTURAL
CONDITIONS
20
2.1.
INTRODUCTION
..................................................................................................................................
20
2.1.1.
MULTIDISCIPLINARY
APPROACH
.............................................................................................................
20
2.1.2.
RADIOEMBOLISATION
TEAM
(TARE
WORKING
GROUP)
..............................................................................
20
2.2.
LEGAL
REQUIREMENTS
FOR
THE
PERFORMANCE
OF
RADIOEMBOLISATION
IN
HOSPITALS
............................
21
2.3.
INFRASTRUCTURAL
REQUIREMENTS
FOR
THE
PERFORMANCE
OF
RADIOEMBOLISATION
IN
HOSPITALS
.............
21
2.3.1.
APPROPRIATE
INSTITUTIONS
..................................................................................................................
21
2.3.2.
TRAINING
COURSES
FOR
INTERVENTIONAL
RADIOLOGISTS
AND
SPECIALISTS
IN
NUCLEAR
MEDICINE
......................
22
2.3.3.
DIAGNOSTIC
EQUIPMENT
.....................................................................................................................
22
2.3.4.
RADIATION
PROTECTION
......................................................................................................................
22
2.3.4.1.
ANGIOGRAPHY
SUITE
...........................................................................................................................
22
2.3.4.2.
ANGIOGRAPHY
CATHETER
AND
FURTHER
MEDICAL
DISPOSABLES
.......................................................................
22
2.3.4.3.
MEDICAL
STAFF
AND
OTHER
PERSONS
.........................................................................................................
22
2.3.4.4.
PATIENTS
............................................................................................................................................
23
2.4.
REFERENCES......................................................................................................................................
23
HH
BASICS
OF
RADIOEMBOLISATION
AND
CLINICAL
USE
OF
MICROSPHERES
26
3.1.
RADIOEMBOLISATION
..........................................................................................................................
26
3.1.1.
MODE
OF
ACTION
................................................................................................................................
26
3.2.
YTTRIUM-90
MICROSPHERES
...............................................................................................................
27
3.2.1.
HISTORICAL
DEVELOPMENT
....................................................................................................................
27
3.2.2.
MATERIALS
AND
PHYSICAL
PRINCIPLES
.....................................................................................................
28
3.2.2.1.
RESIN
SPHERES
....................................................................................................................................
29
3.2.2.2.
GLASS
SPHERES
....................................................................................................................................
29
3.2.3.
REFERENCES
FOR
CHAPTERS
3.1.
AND
3.2.
.............................................................................................
30
3.3.
HOLMIUM-1
66
MICROSPHERES
.........................................................................................................
30
3.3.1.
HISTORICAL
DEVELOPMENT
....................................................................................................................
30
3.3.2.
MATERIALS
AND
PHYSICAL
PRINCIPLES
.....................................................................................................
31
3.3.3.
CLINICAL
CHARACTERISTICS
....................................................................................................................
32
3.3.4.
IMAGING
...........................................................................................................................................
32
3.3.5.
IMAGING
...........................................................................................................................................
33
3.3.5.1.
HO
SPECT-CT
.................................................................................................................................
33
3.3.5.2.
HO
MRI
..........................................................................................................................................
33
3.3.5.3.
WORK-UP
WITH
A
HOLMIUM-1
66
SCOUT
DOSE
............................................................................................
33
3.3.6.
RESULTS
OF
CLINICAL
STUDIES
................................................................................................................
34
3.3.6.1
.
ONGOING
STUDIES
IN
THE
NETHERLANDS...................................................................................................
35
3.3.7.
FUTURE
PERSPECTIVES
...............................................................................
36
3.3.8.
SUMMARY
.................................................
37
3.3.9.
REFERENZES
FOR
CHAPTER
3.3
..............................................................................................................
37
INDICATIONS
FOR
TREATMENT
AND
PATIENT
SELECTION
42
4.1.
INTRODUCTION
..................................................................................................................................
42
4.2.
INDICATIONS
AND
CONTRAINDICATIONS
..............................................................................................
42
4.3.
HEPATOCELLULAR
CARCINOMA
IN
CIRRHOTIC
LIVER
-
A
SPECIAL
CHALLENGE
..............................................
46
4.4.
SUMMARY
.......................................................................................................................................
46
12
CONTENTS
4.5.
REFERENCES
.......................................................................................................................................
47
TARE
FROM
SURGEONS
POINT
OF
VIEW
50
5.1.
TARE
AND
LIVER
SURGERY
..................................................................................................................
50
5.2.
ROLE
OF
SURGERY
IN
THE
TREATMENT
OF
LIVER
TUMORS
.........................................................................
50
5.3.
RESIDUAL
LIVER
VOLUME
LIMITS
SURGICAL
TREATMENT
..........................................................................
50
5.4.
COMBINATION
OF
DIFFERENT
PROCEDURES
ALLOWS
MORE
FREQUENT
CURATIVE
SURGICAL
THERAPY
.........
50
5.5.
EFFECT
OF
TARE
ON
TUMOR
AND
LIVER
TISSUE
AND
RELATED
STRATEGIES
BEFORE
SURGICAL
RESECTION.
...
51
5.5.1.
TARE
TO
IMPROVE
LOCAL
RESECTABILITY
..................................................................................................
51
5.5.2.
TARE
FOR
LOCAL
TUMOR
CONTROLL
..........................................................................................................
52
5.5.3.
TARE
FOR
INDUCTION
OF
LIVER
HYPERTROPHY
..........................................................................................
52
5.5.4.
TARE
AS
PALLIATIVE
THERAPY
...............................................................................................................
52
5.6.
TARE
AND
LIVER
SURGERY
-
CURRENT
REFERENCES
.....................
.........................................................
52
5.7.
OWN
EXPERIENCES
..........................................................................................................................
53
5.7.1.
KARLSRUHE
TARE
BOARD
......................................................................................................................
54
5.8.
FUTURE
.............................................................................................................................................
54
5.9.
REFERENCES
......................................................................................................................................
54
TARE
FROM
NUCLEAR
MEDICINE
SPECIALISTS
POINT
OF
VIEW
58
6.1.
TREATMENT
PLANNING
.......................................................................................................................
58
6.1.1.
PLANAR
SCINTIGRAPHY
AND
SPECT
OR
SPECT-CT
WITH
TC
MAA
OR
RADIOLABELED
MICROSPHERES
............
58
6.1.2.
CONCEPTS
FOR
THE
CALCULATION
OF
THERAPY
ACTIVITY
...............................................................................
61
6.1.3.
CONSIDERATIONS
CONCERNING
ACHIEVABLE
FOCAL
DOSE
...........................................................................
62
6.2.
PERFORMANCE
OF
THERAPY
................................................................................................................
63
6.3.
POST-THERAPY
SCAN
..........................................................................................................................
65
6.3.1.
BREMSSTRAHLEN
SCINTIGRAPHY
..............................................................................................................
65
6.3.2.
POST-THERAPEUTIC
DISTRIBUTION
IMAGING
USING
PET
...........................................................................
65
6.3.3.
POST-THERAPEUTIC
DISTRIBUTION
IMAGING
FOR
HO
..............................................................................
66
6.4.
PRE
AND
POST-THERAPEUTIC
CARE
ON
WARD
......................................................................................
66
6.5.
REFERENCES
......................................................................................................................................
67
TARE
FROM
RADIOLOGISTS
POINT
OF
VIEW
70
7.1.
INTRODUCTION
...................................................................................................................................
70
7.2.
RADIOLOGICAL
IMAGING
BEFORE
THERAPY
..........................................................................................
70
7.2.1.
ULTRASOUND
.......................................................................................................................................
70
7.2.2.
MULTIPLE
DETECTOR
COMPUTED
TOMOGRAPHY
(MDCT)
..........................................................................
71
7.2.3.
PET
CT
.............................................................................................................................................
72
7.2.4.
MAGNETIC
RESONANCE
IMAGING
(MRI)
.................................................................
73
7.2.5.
MN
TC
MAA
ANGIOGRAPHY
...................................................................................................................
75
7.3.
TREATMENT
......................................................................................................................................
75
7.3.1.
ANGIOGRAPHIC
PROCEDURE
DURING
THERAPY
........................................................................................
75
7.4.
RADIOLOGICAL
FOLLOW-UP
..................................................................................................................
76
7.4.1.
RECIST
AND
MODIFIED
RECIST
............................................................................................................
76
7.4.2.
RECOMMENDATED
FOLLOW-UP
.............................................................................................................
77
7.5.
REFERENCES......................................................................................................................................
78
TIPS
AND
TRICKS
FOR
USING
ANGIOGRAPHY
82
8.1.
INTRODUCTION
...................................................................................................................................
82
8.2.
MM
TC
MAA
ANGIOGRAPHY:
TECHNIQUE
AND
MATERIAL
.......................................................................
82
CONTENTS
13
8.3.
FREQUENT
ANATOMICAL
NORM
VARIANTS
..............................................................................................
84
8.3.1.
LEFT
GASTROHEPATIC
TRUNK
..................................................................................................................
84
8.3.2.
HEPATOMESENTERIC
TRUNK
..................................................................................................................
86
8.3.3.
CELIAC
TRUNK
COMPRESSION
SYNDROME
..............................................................................................
87
8.4.
ABERRANT
AND
HIGH
RISK
VESSELS
......................................................................................................
88
8.4.1.
GASTRODUODENAL
ARTERY
....................................................................................................................
88
8.4.2.
CYSTIC
ARTERY
.....................................................................................................................................
89
8.4.3.
RIGHT
GASTRIC
ARTERY
.........................................................................................................................
91
8.4.4.
HEPATIC
FALCIFORM
ARTERY
...................................................................................................................
91
8.4.5.
LOWER
ESOPHAGEAL
BRANCHES
...........................................................................................................
92
8.5.
INTRAHEPATIC
SHUNTS
......................................................................................................................
93
8.5.1.
ARTERIOPORTAL
AND
ARTERIOVENOUS
SHUNTS
..........................................................................................
93
8.6.
RADIOEMBOLISATION
........................................................................................................................
94
H
RESULTS
OF
TARE
96
9.1.
PRIMARY
LIVER
CANCER
......................................................................................................................
96
9.1.1.
HEPATOCELLULAR
CARCINOMA
(HCC).....................................................................................................
96
9.1.2.
INTRAHEPATIC
CHOLANGIOCARCINOMA
(ICC)
............................................................................................
96
9.2.
METASTASES
....................................................................................................................................
97
9.2.1.
COLORECTAL
CANCER
(CRC)
...................................................................................................................
97
9.2.2.
NEUROENDOCRINE
TUMORS
(NET)
........................................................................................................
97
9.2.3.
BREAST
CANCER...................................................................................................................................
98
9.3.
SUMMARY
.......................................................................................................................................
98
9.4.
REFERENCES......................................................................................................................................
98
SIDE
EFFECTS
AND
COMPLICATIONS
102
10.1.
EXTRAHEPATIC
COMPLICATIONS
........................................................................................................
102
10.1.1.
PANCYTOPENIA
AND
LYMPHOPENIA
....................................................................................................
102
10.1.2.
RADIATION-INDUCED
PNEUMONIA
.....................................................................................................
102
10.1.3.
GASTROINTESTINAL
AND
PANCREATIC
COMPLICATIONS
.............................................................................
102
10.2.
INTRAHEPATIC
COMPLICATIONS
..........................................................................................................
103
10.2.1.
RADIATION-INDUCED
CHOLECYSTITIS
.....................................................................................................
103
10.2.2.
COMPLICATIONS
OF
THE
BILE
DUCT
SYSTEM
..........................................................................................
103
10.2.3.
RADIOEMBOLISATION
INDUCED
LIVER
DISEASE
(REILD)
..........................................................................
103
10.3.
SUMMARY
......................................................................................................................................
104
10.4.
REFERENCES
..................................................................................................................................
104
OUTLOOK
-
PERSPECTIVES
FOR
TARE
106
11.1.
RADIOEMBOLISATION
AS
ADJUVANT
OR
IN
COMBINATION
WITH
SYSTEMIC
THERAPIES
............................
106
11.2.
RADIOEMBOLISATION
-
PHYSICO-TECHNICAL
DEVELOPMENTS
............................................................
107
11.3.
REFERENCES
..................................................................................................................................
107
ANNEX
110
12.1.
LIST
OF
ABBREVIATIONS
...................................................................................................................
110
12.2.
MANUFACTURERS
.............................................................................................................................
110
12.2.1.
MANUFACTURERS
OF
SPHERES
.............................................................................................................
111
12.2.2.
MANUFACTURERS
OFCOILS
...................................................................................................................
ILL
12.2.3.
MANUFACTURERS
OF
CATHETERS
AND
ANGIOGRAPHY
SUPPLIES
..................................................................
111
INDEX
112
|
| adam_txt |
CONTENTS
11
CONTENTS
M
INTRODUCTION
16
1.1.
REFERENCES.
17
M
LEGAL
AND
INFRASTRUCTURAL
CONDITIONS
20
2.1.
INTRODUCTION
.
20
2.1.1.
MULTIDISCIPLINARY
APPROACH
.
20
2.1.2.
RADIOEMBOLISATION
TEAM
(TARE
WORKING
GROUP)
.
20
2.2.
LEGAL
REQUIREMENTS
FOR
THE
PERFORMANCE
OF
RADIOEMBOLISATION
IN
HOSPITALS
.
21
2.3.
INFRASTRUCTURAL
REQUIREMENTS
FOR
THE
PERFORMANCE
OF
RADIOEMBOLISATION
IN
HOSPITALS
.
21
2.3.1.
APPROPRIATE
INSTITUTIONS
.
21
2.3.2.
TRAINING
COURSES
FOR
INTERVENTIONAL
RADIOLOGISTS
AND
SPECIALISTS
IN
NUCLEAR
MEDICINE
.
22
2.3.3.
DIAGNOSTIC
EQUIPMENT
.
22
2.3.4.
RADIATION
PROTECTION
.
22
2.3.4.1.
ANGIOGRAPHY
SUITE
.
22
2.3.4.2.
ANGIOGRAPHY
CATHETER
AND
FURTHER
MEDICAL
DISPOSABLES
.
22
2.3.4.3.
MEDICAL
STAFF
AND
OTHER
PERSONS
.
22
2.3.4.4.
PATIENTS
.
23
2.4.
REFERENCES.
23
HH
BASICS
OF
RADIOEMBOLISATION
AND
CLINICAL
USE
OF
MICROSPHERES
26
3.1.
RADIOEMBOLISATION
.
26
3.1.1.
MODE
OF
ACTION
.
26
3.2.
YTTRIUM-90
MICROSPHERES
.
27
3.2.1.
HISTORICAL
DEVELOPMENT
.
27
3.2.2.
MATERIALS
AND
PHYSICAL
PRINCIPLES
.
28
3.2.2.1.
RESIN
SPHERES
.
29
3.2.2.2.
GLASS
SPHERES
.
29
3.2.3.
REFERENCES
FOR
CHAPTERS
3.1.
AND
3.2.
.
30
3.3.
HOLMIUM-1
66
MICROSPHERES
.
30
3.3.1.
HISTORICAL
DEVELOPMENT
.
30
3.3.2.
MATERIALS
AND
PHYSICAL
PRINCIPLES
.
31
3.3.3.
CLINICAL
CHARACTERISTICS
.
32
3.3.4.
IMAGING
.
32
3.3.5.
IMAGING
.
33
3.3.5.1.
'
"
HO
SPECT-CT
.
33
3.3.5.2.
'
"
HO
MRI
.
33
3.3.5.3.
WORK-UP
WITH
A
HOLMIUM-1
66
SCOUT
DOSE
.
33
3.3.6.
RESULTS
OF
CLINICAL
STUDIES
.
34
3.3.6.1
.
ONGOING
STUDIES
IN
THE
NETHERLANDS.
35
3.3.7.
FUTURE
PERSPECTIVES
.
36
3.3.8.
SUMMARY
.
37
3.3.9.
REFERENZES
FOR
CHAPTER
3.3
.
37
INDICATIONS
FOR
TREATMENT
AND
PATIENT
SELECTION
42
4.1.
INTRODUCTION
.
42
4.2.
INDICATIONS
AND
CONTRAINDICATIONS
.
42
4.3.
HEPATOCELLULAR
CARCINOMA
IN
CIRRHOTIC
LIVER
-
A
SPECIAL
CHALLENGE
.
46
4.4.
SUMMARY
.
46
12
CONTENTS
4.5.
REFERENCES
.
47
TARE
FROM
SURGEONS
POINT
OF
VIEW
50
5.1.
TARE
AND
LIVER
SURGERY
.
50
5.2.
ROLE
OF
SURGERY
IN
THE
TREATMENT
OF
LIVER
TUMORS
.
50
5.3.
RESIDUAL
LIVER
VOLUME
LIMITS
SURGICAL
TREATMENT
.
50
5.4.
COMBINATION
OF
DIFFERENT
PROCEDURES
ALLOWS
MORE
FREQUENT
CURATIVE
SURGICAL
THERAPY
.
50
5.5.
EFFECT
OF
TARE
ON
TUMOR
AND
LIVER
TISSUE
AND
RELATED
STRATEGIES
BEFORE
SURGICAL
RESECTION.
.
51
5.5.1.
TARE
TO
IMPROVE
LOCAL
RESECTABILITY
.
51
5.5.2.
TARE
FOR
LOCAL
TUMOR
CONTROLL
.
52
5.5.3.
TARE
FOR
INDUCTION
OF
LIVER
HYPERTROPHY
.
52
5.5.4.
TARE
AS
PALLIATIVE
THERAPY
.
52
5.6.
TARE
AND
LIVER
SURGERY
-
CURRENT
REFERENCES
.
.
52
5.7.
OWN
EXPERIENCES
.
53
5.7.1.
KARLSRUHE
TARE
BOARD
.
54
5.8.
FUTURE
.
54
5.9.
REFERENCES
.
54
TARE
FROM
NUCLEAR
MEDICINE
SPECIALISTS
POINT
OF
VIEW
58
6.1.
TREATMENT
PLANNING
.
58
6.1.1.
PLANAR
SCINTIGRAPHY
AND
SPECT
OR
SPECT-CT
WITH
"
"TC
MAA
OR
RADIOLABELED
MICROSPHERES
.
58
6.1.2.
CONCEPTS
FOR
THE
CALCULATION
OF
THERAPY
ACTIVITY
.
61
6.1.3.
CONSIDERATIONS
CONCERNING
ACHIEVABLE
FOCAL
DOSE
.
62
6.2.
PERFORMANCE
OF
THERAPY
.
63
6.3.
POST-THERAPY
SCAN
.
65
6.3.1.
BREMSSTRAHLEN
SCINTIGRAPHY
.
65
6.3.2.
POST-THERAPEUTIC
DISTRIBUTION
IMAGING
USING
PET
.
65
6.3.3.
POST-THERAPEUTIC
DISTRIBUTION
IMAGING
FOR
'
"
HO
.
66
6.4.
PRE
AND
POST-THERAPEUTIC
CARE
ON
WARD
.
66
6.5.
REFERENCES
.
67
TARE
FROM
RADIOLOGISTS
POINT
OF
VIEW
70
7.1.
INTRODUCTION
.
70
7.2.
RADIOLOGICAL
IMAGING
BEFORE
THERAPY
.
70
7.2.1.
ULTRASOUND
.
70
7.2.2.
MULTIPLE
DETECTOR
COMPUTED
TOMOGRAPHY
(MDCT)
.
71
7.2.3.
PET
CT
.
72
7.2.4.
MAGNETIC
RESONANCE
IMAGING
(MRI)
.
73
7.2.5.
MN
TC
MAA
ANGIOGRAPHY
.
75
7.3.
TREATMENT
.
75
7.3.1.
ANGIOGRAPHIC
PROCEDURE
DURING
THERAPY
.
75
7.4.
RADIOLOGICAL
FOLLOW-UP
.
76
7.4.1.
RECIST
AND
MODIFIED
RECIST
.
76
7.4.2.
RECOMMENDATED
FOLLOW-UP
.
77
7.5.
REFERENCES.
78
TIPS
AND
TRICKS
FOR
USING
ANGIOGRAPHY
82
8.1.
INTRODUCTION
.
82
8.2.
MM
TC
MAA
ANGIOGRAPHY:
TECHNIQUE
AND
MATERIAL
.
82
CONTENTS
13
8.3.
FREQUENT
ANATOMICAL
NORM
VARIANTS
.
84
8.3.1.
LEFT
GASTROHEPATIC
TRUNK
.
84
8.3.2.
HEPATOMESENTERIC
TRUNK
.
86
8.3.3.
CELIAC
TRUNK
COMPRESSION
SYNDROME
.
87
8.4.
ABERRANT
AND
HIGH
RISK
VESSELS
.
88
8.4.1.
GASTRODUODENAL
ARTERY
.
88
8.4.2.
CYSTIC
ARTERY
.
89
8.4.3.
RIGHT
GASTRIC
ARTERY
.
91
8.4.4.
HEPATIC
FALCIFORM
ARTERY
.
91
8.4.5.
LOWER
ESOPHAGEAL
BRANCHES
.
92
8.5.
INTRAHEPATIC
SHUNTS
.
93
8.5.1.
ARTERIOPORTAL
AND
ARTERIOVENOUS
SHUNTS
.
93
8.6.
RADIOEMBOLISATION
.
94
H
RESULTS
OF
TARE
96
9.1.
PRIMARY
LIVER
CANCER
.
96
9.1.1.
HEPATOCELLULAR
CARCINOMA
(HCC).
96
9.1.2.
INTRAHEPATIC
CHOLANGIOCARCINOMA
(ICC)
.
96
9.2.
METASTASES
.
97
9.2.1.
COLORECTAL
CANCER
(CRC)
.
97
9.2.2.
NEUROENDOCRINE
TUMORS
(NET)
.
97
9.2.3.
BREAST
CANCER.
98
9.3.
SUMMARY
.
98
9.4.
REFERENCES.
98
SIDE
EFFECTS
AND
COMPLICATIONS
102
10.1.
EXTRAHEPATIC
COMPLICATIONS
.
102
10.1.1.
PANCYTOPENIA
AND
LYMPHOPENIA
.
102
10.1.2.
RADIATION-INDUCED
PNEUMONIA
.
102
10.1.3.
GASTROINTESTINAL
AND
PANCREATIC
COMPLICATIONS
.
102
10.2.
INTRAHEPATIC
COMPLICATIONS
.
103
10.2.1.
RADIATION-INDUCED
CHOLECYSTITIS
.
103
10.2.2.
COMPLICATIONS
OF
THE
BILE
DUCT
SYSTEM
.
103
10.2.3.
RADIOEMBOLISATION
INDUCED
LIVER
DISEASE
(REILD)
.
103
10.3.
SUMMARY
.
104
10.4.
REFERENCES
.
104
OUTLOOK
-
PERSPECTIVES
FOR
TARE
106
11.1.
RADIOEMBOLISATION
AS
ADJUVANT
OR
IN
COMBINATION
WITH
SYSTEMIC
THERAPIES
.
106
11.2.
RADIOEMBOLISATION
-
PHYSICO-TECHNICAL
DEVELOPMENTS
.
107
11.3.
REFERENCES
.
107
ANNEX
110
12.1.
LIST
OF
ABBREVIATIONS
.
110
12.2.
MANUFACTURERS
.
110
12.2.1.
MANUFACTURERS
OF
SPHERES
.
111
12.2.2.
MANUFACTURERS
OFCOILS
.
ILL
12.2.3.
MANUFACTURERS
OF
CATHETERS
AND
ANGIOGRAPHY
SUPPLIES
.
111
INDEX
112 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Hoffmann, Ralf-Thorsten 1971- Zöphel, Klaus 1967- |
| author_GND | (DE-588)122135326 (DE-588)121035808 |
| author_facet | Hoffmann, Ralf-Thorsten 1971- Zöphel, Klaus 1967- |
| author_role | aut aut |
| author_sort | Hoffmann, Ralf-Thorsten 1971- |
| author_variant | r t h rth k z kz |
| building | Verbundindex |
| bvnumber | BV048418449 |
| ctrlnum | (OCoLC)1289783490 (DE-599)DNB1247562921 |
| dewey-full | 615.842 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.842 |
| dewey-search | 615.842 |
| dewey-sort | 3615.842 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| edition | 1st edition |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02467nam a2200541 c 4500</leader><controlfield tag="001">BV048418449</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">220823s2021 gw a||| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">21,N51</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">22,A21</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1247562921</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783837416039</subfield><subfield code="c">Festeinband : EUR 4.95 (DE), EUR 5.10 (AT), CHF 9.40 (freier Preis)</subfield><subfield code="9">978-3-8374-1603-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3837416038</subfield><subfield code="9">3-8374-1603-8</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783837416039</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1289783490</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1247562921</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-HB</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">615.842</subfield><subfield code="2">23/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">1\p</subfield><subfield code="a">610</subfield><subfield code="2">23sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hoffmann, Ralf-Thorsten</subfield><subfield code="d">1971-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)122135326</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Transarterial radioembolisation (TARE) - basics and clinical use</subfield><subfield code="c">Ralf-Thorsten Hoffmann, Klaus Zöphel ; in collaboration with Mark Arntz [und weiteren]</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen</subfield><subfield code="b">UNI-MED Verlag AG</subfield><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">112 Seiten</subfield><subfield code="b">Illustrationen</subfield><subfield code="c">25 cm, 359 g</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED science</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">SIRT</subfield><subfield code="0">(DE-588)7626011-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Transarterial radioembolisation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TARE</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SIRT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Transarterial radioembolisation;TARE;SIRT</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">SIRT</subfield><subfield code="0">(DE-588)7626011-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zöphel, Klaus</subfield><subfield code="d">1967-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)121035808</subfield><subfield code="4">aut</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">UNI-MED Verlag AG</subfield><subfield code="0">(DE-588)1065561733</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="a">Hoffmann, Ralf-Thorsten, 1971-</subfield><subfield code="t">Transarterial radioembolisation (TARE) – basics and clinical use</subfield><subfield code="b">1. Auflage</subfield><subfield code="d">Bremen : UNI-MED Verlag AG, 2021</subfield><subfield code="h">Online-Ressource, 111 Seiten, 80 Illustrationen</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="q">text/html</subfield><subfield code="u">http://deposit.dnb.de/cgi-bin/dokserv?id=dc24957538c2477b9a4e1e7ccc6a7b1e&prov=M&dok_var=1&dok_ext=htm</subfield><subfield code="3">Inhaltstext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">B:DE-101</subfield><subfield code="q">application/pdf</subfield><subfield code="u">https://d-nb.info/1247562921/04</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033796786&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033796786</subfield></datafield><datafield tag="883" ind1="2" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">dnb</subfield><subfield code="d">20220518</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#dnb</subfield></datafield></record></collection> |
| id | DE-604.BV048418449 |
| illustrated | Illustrated |
| index_date | 2024-07-03T20:27:01Z |
| indexdate | 2024-07-10T09:37:40Z |
| institution | BVB |
| institution_GND | (DE-588)1065561733 |
| isbn | 9783837416039 3837416038 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033796786 |
| oclc_num | 1289783490 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | 112 Seiten Illustrationen 25 cm, 359 g |
| publishDate | 2021 |
| publishDateSearch | 2021 |
| publishDateSort | 2021 |
| publisher | UNI-MED Verlag AG |
| record_format | marc |
| series2 | UNI-MED science |
| spelling | Hoffmann, Ralf-Thorsten 1971- Verfasser (DE-588)122135326 aut Transarterial radioembolisation (TARE) - basics and clinical use Ralf-Thorsten Hoffmann, Klaus Zöphel ; in collaboration with Mark Arntz [und weiteren] 1st edition Bremen UNI-MED Verlag AG 2021 112 Seiten Illustrationen 25 cm, 359 g txt rdacontent n rdamedia nc rdacarrier UNI-MED science SIRT (DE-588)7626011-2 gnd rswk-swf Transarterial radioembolisation TARE SIRT Transarterial radioembolisation;TARE;SIRT SIRT (DE-588)7626011-2 s DE-604 Zöphel, Klaus 1967- Verfasser (DE-588)121035808 aut UNI-MED Verlag AG (DE-588)1065561733 pbl Erscheint auch als Online-Ausgabe Hoffmann, Ralf-Thorsten, 1971- Transarterial radioembolisation (TARE) – basics and clinical use 1. Auflage Bremen : UNI-MED Verlag AG, 2021 Online-Ressource, 111 Seiten, 80 Illustrationen X:MVB text/html http://deposit.dnb.de/cgi-bin/dokserv?id=dc24957538c2477b9a4e1e7ccc6a7b1e&prov=M&dok_var=1&dok_ext=htm Inhaltstext B:DE-101 application/pdf https://d-nb.info/1247562921/04 Inhaltsverzeichnis DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033796786&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p dnb 20220518 DE-101 https://d-nb.info/provenance/plan#dnb |
| spellingShingle | Hoffmann, Ralf-Thorsten 1971- Zöphel, Klaus 1967- Transarterial radioembolisation (TARE) - basics and clinical use SIRT (DE-588)7626011-2 gnd |
| subject_GND | (DE-588)7626011-2 |
| title | Transarterial radioembolisation (TARE) - basics and clinical use |
| title_auth | Transarterial radioembolisation (TARE) - basics and clinical use |
| title_exact_search | Transarterial radioembolisation (TARE) - basics and clinical use |
| title_exact_search_txtP | Transarterial radioembolisation (TARE) - basics and clinical use |
| title_full | Transarterial radioembolisation (TARE) - basics and clinical use Ralf-Thorsten Hoffmann, Klaus Zöphel ; in collaboration with Mark Arntz [und weiteren] |
| title_fullStr | Transarterial radioembolisation (TARE) - basics and clinical use Ralf-Thorsten Hoffmann, Klaus Zöphel ; in collaboration with Mark Arntz [und weiteren] |
| title_full_unstemmed | Transarterial radioembolisation (TARE) - basics and clinical use Ralf-Thorsten Hoffmann, Klaus Zöphel ; in collaboration with Mark Arntz [und weiteren] |
| title_short | Transarterial radioembolisation (TARE) - basics and clinical use |
| title_sort | transarterial radioembolisation tare basics and clinical use |
| topic | SIRT (DE-588)7626011-2 gnd |
| topic_facet | SIRT |
| url | http://deposit.dnb.de/cgi-bin/dokserv?id=dc24957538c2477b9a4e1e7ccc6a7b1e&prov=M&dok_var=1&dok_ext=htm https://d-nb.info/1247562921/04 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033796786&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT hoffmannralfthorsten transarterialradioembolisationtarebasicsandclinicaluse AT zophelklaus transarterialradioembolisationtarebasicsandclinicaluse AT unimedverlagag transarterialradioembolisationtarebasicsandclinicaluse |